This CPB has been revised to state that bortezomib is considered medically necessary for adult T-cell leukemia/lymphoma, Sezary syndrome, and as second-line therapy for primary cutaneous marginal zone or follicle center lymphoma. This CPB is revised to state that bortezomib is considered experimental and investigational for histiocytic sarcoma, liver transplant rejection, and post-transplant lymphoproliferative disorder.